TY  - JOUR
T1  - Paradigm of immune dysregulation in coronavirus disease-2019 infection
AU  - Sahoo, Om Saswat
AU  - Pethusamy, Karthikeyan
AU  - Nayek, Arnab
AU  - Minocha, Rashmi
AU  - Dhar, Ruby
AU  - Karmakar, Subhradip
Y1  - 2024///
JO  - Exploration of Immunology
VL  - 4
IS  - 1
SP  - 1
EP  - 33
DO  - 10.37349/ei.2024.00126
UR  - https://www.explorationpub.com/Journals/ei/Article/1003126
AB  - The coronavirus disease 2019 (COVID-19) pandemic cost 7–8 million deaths worldwide, creating an unprecedented health and economic crisis. Affecting 700 million people globally, the magnitude of this pandemic is far from anything that humanity has encountered in recent times. A detailed investigation revealed that more than the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the hyperactive immune system mediated injury as the real cause of mortality. Cytokine storm following viral infection leads to the surge of proinflammatory cytokines resulting in acute respiratory distress syndrome (ARDS) and lung injury. Anti-inflammatory intervention with anti-interleukin-6 (anti-IL-6) receptor monoclonal antibodies (mAbs; e.g., sarilumab and tocilizumab) and anti-IL-6 mAbs (i.e., siltuximab) and/or steroid-based approach leads to substantial protection and prevent death thereby implying the role of inflammation in COVID-19. In this review, the authors have summarized the dysregulated immune system in COVID-19 infection, investigating in detail the virus-host immune cross talks and presenting the possibilities of therapeutic intervention.
ER  -